Press Releases


12th December 2016: Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
25th August 2016: Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.
24th November 2015: Paras Biopharmaceuticals forms partnership with Novozymes to embrace Veltis® technology for once-a-week Teriparatide Biobetter for Osteoporosis
28th April 2015: Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum
11th December 2014: Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan

To view award report, click on the link below

Award Report

*NEW* Photos of Award Ceremony and Banquet


Media Contact

Dr. Mark Jackson
Public Affairs
mark.jackson@parasbiopharma.com